ArticleDiabetes, obesity & metabolism2025
Impact of onset age of type 2 diabetes mellitus on risk of renal complications compared to age-matched non-diabetic patients: Two cohort studies in the United Kingdom and Hong Kong.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of novel genomic variants in diabetic nephropathy patients using whole-exome sequencing: a pilot investigation.Frontiers in endocrinology · 2026Article
- Impact of onset age of type 2 diabetes mellitus on risk of renal complications compared to age-matched non-diabetic patients: Two cohort studies in the United Kingdom and Hong Kong.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWith the increasing incidence of early-onset type 2 diabetes mellitus (T2DM) and the significant burden of renal complications in younger patients, this study aimed to investigate the association between the age at onset of T2DM and the risks of renal complications.
methodsTwo retrospective cohort studies were conducted among adults without chronic kidney disease (CKD) from 2008 to 2013, utilising electronic health records from the United Kingdom (UK) and Hong Kong (HK). A total of 124 610 and 183 114 patients newly diagnosed with T2DM were included in the T2DM group, and 4 968 819 and 3 290 862 individuals without diabetes were included in the comparison group for the UK and HK cohorts, respectively. Participants were categorised into six age groups at baseline (18-39, 40-49, 50-59, 60-69, 70-79, and ≥ 80 years). Propensity score fine stratification weights were applied within each age group, and Cox regression analyses were performed to evaluate the association between T2DM and the risks of renal complications, including CKD, renal decline, and end-stage renal disease (ESRD).
resultsOver a median followup of 11.6 years (approximately 57 million person-years) in the UK cohort and 9.7 years (approximately 35 million person-years) in the HK cohort, T2DM was associated with an increased risk of CKD, renal decline, and ESRD. However, the risks decreased with increasing age at T2DM onset. In the UK cohort, the hazard ratios (HRs) [95% confidence intervals (CIs)] for the three outcomes among individuals with T2DM onset at 18-39 years versus those without diabetes were 1.87 (1.65, 2.11), 4.87 (4.38, 5.40), and 4.49 (3.03, 6.68), respectively. For individuals with T2DM onset at ≥80 years, the HRs decreased to 1.26 (1.21, 1.32), 1.66 (1.55, 1.78), and 1.48 (1.12, 1.96), respectively. A similar trend was observed in the HK cohort, with risks for all outcomes decreasing as the age of T2DM onset increased.
conclusionEarly-onset T2DM is associated with substantially higher risks of CKD, renal decline, and ESRD, underscoring the need for targeted prevention and management strategies to reduce renal complications in younger patients with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.